CA-VISA-INC.
6.12.2018 14:02:22 CET | Business Wire | Press release
Visa (NYSE:V), the Official Payment Services Partner of FIFA, has announced partnerships with the Union of European Football Associations’ (UEFA) Women’s Football Competitions and the Confederation of African Football (CAF) Total Africa Cup of Nations tournament to evolve its sponsorship portfolio and connect with fans around the world. Leveraging its sponsorship expertise and success at the 2018 FIFA World Cup Russia™, Visa will implement its innovative payment technology at the tournament venues and deliver exclusive experiences for cardholders and clients. By tapping into the strength of the Visa brand and its influential role for fans in football, Visa will help to further elevate women’s football and these regional tournaments.
“Visa has strategically positioned itself at the center of football and these events will further exemplify the unique experiences only Visa can provide to fans across the globe,” said Chris Curtin, chief brand and innovation marketing officer, Visa Inc. “These tournaments allow us distinctive opportunities to showcase Visa’s payment innovation, strengthen partnerships and highlight our evolved offerings to clients and fans.”
Expanding Global Football Portfolio
Visa is partnering with the UEFA Women’s Football Competitions through 2025 to continue its efforts to inspire and empower women, as women’s football continues to grow at all levels. Through its partnership, Visa will collaborate with UEFA for the 2021 Women’s European Championships in the United Kingdom and the annual Women’s Champions League beginning in 2019. Complementing the national team tournament with the world’s finest club competition allows Visa to be at the center of women’s football and strengthens its efforts around diversity, acceptance, and inclusion leading up to the FIFA Women's World Cup France 2019™.
Visa also announced its partnership with CAF as a sponsor of the Total Africa Cup of Nations (AFCON) tournament in 2019 and 2021. The deal will make Visa the exclusive payment services provider at all venues and the official partner of the player escort program. With CAF, Visa will be able to capitalize on football’s popularity throughout the continent, tap into high-growth markets and continue to deliver exclusive benefits to its local communities, clients, partners and fans as they come together to support the best of African football.
Driving Innovation around the Fan Experience
Visa, a FIFA partner since 2007, continues to drive toward new payment innovation that provides fans with faster and enhanced experiences at checkout. Whether it be remote and mobile ticket purchasing, contactless payment technology at transit locations, in-seat ordering or new ways to pay for retail, Visa will utilize its transit, retail and commerce expertise to deliver innovative payments that reimagine the fan experience.
These tournaments present an opportunity for the brand to build upon its success of 2018 FIFA World Cup Russia™. Visa brought contactless payment technology to 12 tournament stadiums and curated unforgettable experiences for more than 250 clients and 3,000 consumers who traveled from over a hundred different countries. In 103 markets around the world, Visa partnered with more than 500 issuers and 40 merchants in 24 languages on a variety of FIFA-related activities, whether to run custom marketing programs, host in-market viewing parties or utilize Visa’s exclusive marketing campaign assets to drive mutual business priorities.
FIFA Women's World Cup France 2019™ Ticket Presale for Visa Cardholders
Following the FIFA Women's World Cup France 2019™ Draw on December 8, Visa will offer an exclusive opportunity for cardholders to be the first fans to purchase individual match tickets for the tournament. The exclusive presale phase will take place from December 10 through December 23 and tickets for all matches will be available. FIFA recently announced that 150,000 FIFA Women's World Cup France 2019™ tickets have been sold since package sales opened in September.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , https://usa.visa.com/visa-everywhere/blog.html and @VisaNews .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005237/en/
Contact:
Visa Inc. Sheerin Salimi shesalim@visa.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom